These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 565235)

  • 1. A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings].
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1978 Mar; 62(3):395P. PubMed ID: 565235
    [No Abstract]   [Full Text] [Related]  

  • 2. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Jan; 56(1):59-68. PubMed ID: 943193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK; Pfeiffer RF
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract]   [Full Text] [Related]  

  • 4. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile.
    Bergmann F
    Isr J Med Sci; 1982 Jan; 18(1):177-82. PubMed ID: 6121772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of L-dopa and lergotrile mesylate on the interaction of fluphenazine decanoate and amphetamine-induced stereotypy and mortality.
    Lemberger L; Kellams JJ; Small JG; Rowe H
    Commun Psychopharmacol; 1977; 1(5):501-7. PubMed ID: 564259
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings: The effects of buprenorphine, morphine and pentazocine on turning behaviour and stereotypy induced by apomorphine in the rat.
    Cowan A; Dettmar PW; Walter DS
    J Pharm Pharmacol; 1975 Dec; 27 Suppl?-2():15P. PubMed ID: 2687
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine.
    Loew DM; Jaton AL; Vigouret JM
    Postgrad Med J; 1976; 52suppl 1():40-46. PubMed ID: 822407
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of apomorphine-, bromocriptine- and lergotrile-induced circling behaviour in rats by subsequent haloperidol administration.
    Heal DJ; Green AR; Buylaert WA
    Neuropharmacology; 1980 Jan; 19(1):133-7. PubMed ID: 6102352
    [No Abstract]   [Full Text] [Related]  

  • 9. Methodone interaction with apomorphine- and amphetamine-induced turning.
    Stratten WP
    Res Commun Chem Pathol Pharmacol; 1975 Aug; 11(4):675-8. PubMed ID: 1237160
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of unilateral carotid occlusion on apomorphine-induced turning in rats.
    Mears A; Barnett A
    Arch Int Pharmacodyn Ther; 1974 Sep; 211(1):128-32. PubMed ID: 4477705
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel, fully automated rotometer for the study of turning behavior. Comparison of results under different experimental conditions.
    D'Anna L; Loidl CF; Pecci-Saavedra J; González SA; Soqueff MN; Campastro OJ; Fernández RA
    Acta Physiol Pharmacol Latinoam; 1989; 39(3):255-68. PubMed ID: 2576765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings].
    Jenner P; Marsden CD; Reavill C
    Br J Pharmacol; 1979 May; 66(1):103P-104P. PubMed ID: 572254
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre- and postsynaptic action of bromocriptine: its pharmacological effects on shcizophrenia and neurological diseases.
    Trabucchi M; Andreoli VM; Frattola L; Spano PF
    Adv Biochem Psychopharmacol; 1977; 16():661-5. PubMed ID: 196497
    [No Abstract]   [Full Text] [Related]  

  • 15. Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
    Butterworth RF; Poignant JC; Barbeau A
    Adv Neurol; 1975; 9():307-26. PubMed ID: 1170716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cholinergic agonists on apomorphine-induced stereotyped behavior in the rat.
    Sahakian BJ; Growdon JH; Millington WR; Barr JK; Wurtman RJ
    Commun Psychopharmacol; 1978; 2(3):255-62. PubMed ID: 568059
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurochemical and behavioral correlates of chronic apomorphine administration in the rat.
    Kenny M; Leonard BE
    Adv Biochem Psychopharmacol; 1978; 19():347-9. PubMed ID: 567934
    [No Abstract]   [Full Text] [Related]  

  • 18. Bromocriptine-induced behavioral hypersensitivity: implications for the therapy of parkinsonism.
    Nausieda PA; Weiner WJ; Kanapa DJ; Klawans HL
    Neurology; 1978 Nov; 28(11):1183-8. PubMed ID: 568738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings: CF 25-397 (9, 10-didehydro-6-methyl-8beta-(2-pyridylthiomethyl) ergoline), a new central dopamine receptor agonist.
    Jaton AL; Loew DM; Vigouret JM
    Br J Pharmacol; 1976 Mar; 56(3):371P. PubMed ID: 944059
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential actions of typical and atypical neuroleptic agents on two behavioural effects of apomorphine in the mouse [proceedings].
    Costall B; Naylor RJ; Nohria V
    Br J Pharmacol; 1978 Jun; 63(2):381P-382P. PubMed ID: 27276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.